NZ739645A - Form i of compound a, process for its preparation, and its use in the manufacture of a medicament for treating thyroid hormone resistance-associated diseases - Google Patents

Form i of compound a, process for its preparation, and its use in the manufacture of a medicament for treating thyroid hormone resistance-associated diseases

Info

Publication number
NZ739645A
NZ739645A NZ73964513A NZ73964513A NZ739645A NZ 739645 A NZ739645 A NZ 739645A NZ 73964513 A NZ73964513 A NZ 73964513A NZ 73964513 A NZ73964513 A NZ 73964513A NZ 739645 A NZ739645 A NZ 739645A
Authority
NZ
New Zealand
Prior art keywords
preparation
compound
thyroid hormone
medicament
manufacture
Prior art date
Application number
NZ73964513A
Other languages
English (en)
Inventor
Rebecca Taub
Ii D Hester
Robert Duguid
Martha Kelly
Anna Chasnoff
Gang Dong
Edwin Crow
Charles Reynolds
Duk Choi
Lianhe Shu
Ping Wang
Original Assignee
Madrigal Pharmaceuticals Inc
F Hoffmann La Roche Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madrigal Pharmaceuticals Inc, F Hoffmann La Roche Ltd filed Critical Madrigal Pharmaceuticals Inc
Priority to NZ74629513A priority Critical patent/NZ746295A/en
Priority to NZ74629813A priority patent/NZ746298A/en
Publication of NZ739645A publication Critical patent/NZ739645A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
NZ73964513A 2012-09-17 2013-09-17 Form i of compound a, process for its preparation, and its use in the manufacture of a medicament for treating thyroid hormone resistance-associated diseases NZ739645A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NZ74629513A NZ746295A (en) 2012-09-17 2013-09-17 Use of compounds of formula (iv) in the manufacture of a medicament for treating thyroid hormone resistance-associated diseases
NZ74629813A NZ746298A (en) 2012-09-17 2013-09-17 Hydrates of a phenoxypyridazinone compound and its use in the manufacture of a medicament for treating a disease characterized by resistance to thyroid hormone

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261702137P 2012-09-17 2012-09-17
US201361790432P 2013-03-15 2013-03-15
NZ705827A NZ705827A (en) 2012-09-17 2013-09-17 Method of synthesizing thyroid hormone analogs and polymorphs thereof

Publications (1)

Publication Number Publication Date
NZ739645A true NZ739645A (en) 2019-11-29

Family

ID=50278769

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ73964513A NZ739645A (en) 2012-09-17 2013-09-17 Form i of compound a, process for its preparation, and its use in the manufacture of a medicament for treating thyroid hormone resistance-associated diseases
NZ705827A NZ705827A (en) 2012-09-17 2013-09-17 Method of synthesizing thyroid hormone analogs and polymorphs thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ705827A NZ705827A (en) 2012-09-17 2013-09-17 Method of synthesizing thyroid hormone analogs and polymorphs thereof

Country Status (32)

Country Link
US (8) US9266861B2 (enExample)
EP (5) EP4691557A3 (enExample)
JP (8) JP6616688B2 (enExample)
KR (4) KR102138750B1 (enExample)
CN (2) CN108101851A (enExample)
AR (1) AR092872A1 (enExample)
AU (1) AU2013315017C1 (enExample)
BR (2) BR122021024202B1 (enExample)
CA (3) CA2884481C (enExample)
DK (3) DK2895466T3 (enExample)
ES (3) ES2907926T3 (enExample)
FI (2) FI4406594T3 (enExample)
FR (1) FR26C1009I1 (enExample)
HR (1) HRP20251398T1 (enExample)
IL (7) IL314360B2 (enExample)
IN (1) IN2015DN03133A (enExample)
LT (2) LT4406594T (enExample)
MX (2) MX395148B (enExample)
MY (1) MY170520A (enExample)
NL (1) NL301369I2 (enExample)
NO (1) NO2026010I1 (enExample)
NZ (2) NZ739645A (enExample)
PL (1) PL4406594T3 (enExample)
PT (1) PT4406594T (enExample)
RS (1) RS67728B1 (enExample)
RU (2) RU2668960C2 (enExample)
SG (3) SG10202006058QA (enExample)
SI (1) SI4406594T1 (enExample)
SM (1) SMT202500439T1 (enExample)
TW (4) TWI681957B (enExample)
WO (1) WO2014043706A1 (enExample)
ZA (1) ZA201501795B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2884481C (en) * 2012-09-17 2021-04-27 Madrigal Pharmaceuticals, Inc. Method of synthesizing thyroid hormone analogs and polymorphs thereof
CN110167557A (zh) * 2016-10-18 2019-08-23 马德里加尔制药公司 用thr-beta兴奋剂治疗肝脏疾病或脂质疾病的方法
JP7156722B2 (ja) 2018-01-23 2022-10-19 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ピリダジノン化合物
PT3807267T (pt) 2018-06-12 2025-05-22 Xizang Haisco Pharmaceutical Co Ltd Agonistas do recetor da hormona da tiroide e usos dos mesmos
US20210292304A1 (en) * 2018-06-22 2021-09-23 Hinova Pharmaceuticals Inc. Deuterated mgl-3196 compound and use thereof
AR115666A1 (es) * 2018-07-02 2021-02-10 Madrigal Pharmaceuticals Inc Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo
CN119552152A (zh) 2018-10-12 2025-03-04 益方生物科技(上海)股份有限公司 甲状腺激素受体激动剂
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
EP3927693B1 (en) 2019-02-21 2026-05-06 Nanjing Ruijie Pharma Co., Ltd. 2-phenyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile derivatives and similar compounds as thyroid hormone receptor agonists for the treatment of e.g. obesity
MX2021013472A (es) * 2019-05-08 2022-01-06 Aligos Therapeutics Inc Moduladores de thr-? y metodos de uso de estos.
WO2020228577A1 (zh) * 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
WO2020239076A1 (zh) * 2019-05-29 2020-12-03 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021043185A1 (en) * 2019-09-04 2021-03-11 Sunshine Lake Pharma Co., Ltd. A compound as a thyroid hormone beta receptor agonist and use thereof
EP4028008A4 (en) 2019-09-12 2023-09-13 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021063367A1 (zh) * 2019-09-30 2021-04-08 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
CN112707892A (zh) * 2019-10-24 2021-04-27 苏州泽璟生物制药股份有限公司 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物
CN113454069B (zh) * 2019-11-26 2025-03-14 昆药集团股份有限公司 1，2，4-三嗪-3，5-二酮类化合物及其制备方法和应用
WO2021121210A1 (zh) * 2019-12-16 2021-06-24 江苏恒瑞医药股份有限公司 并环类衍生物、其制备方法及其在医药上的应用
CN114787153A (zh) 2019-12-26 2022-07-22 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
US20230339911A1 (en) * 2020-08-27 2023-10-26 InventisBio Co., Ltd. Pyridazinone compounds
CN116171275B (zh) * 2020-09-10 2025-09-05 苏州科睿思制药有限公司 Resmetirom的晶型及其制备方法和用途
CA3195789A1 (en) 2020-10-19 2022-04-28 Teva Pharmaceuticals International Gmbh Solid state forms of resmetirom
CN114437042A (zh) * 2020-11-03 2022-05-06 深圳微芯生物科技股份有限公司 酞嗪类化合物的晶型及其制备方法
CN114437034A (zh) * 2020-11-06 2022-05-06 深圳微芯生物科技股份有限公司 一种酞嗪类化合物的可药用盐、晶型及其制备方法
WO2022165227A1 (en) 2021-02-01 2022-08-04 Madrigal Pharmaceuticals, Inc. Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders
CN114907327A (zh) * 2021-02-10 2022-08-16 杭州领业医药科技有限公司 Resmetirom的晶型及其制备方法和用途
CN115073429A (zh) * 2021-03-15 2022-09-20 昆药集团股份有限公司 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法
CA3233319A1 (en) 2021-09-27 2023-03-30 Rebecca Taub Resmetirom for reducing liver volume
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2024211898A1 (en) 2023-04-07 2024-10-10 Terns Pharmaceuticals, Inc. Combination comprising a thrbeta agonist anda glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease
CN116768802B (zh) * 2023-05-25 2025-11-21 杭州科巢生物科技有限公司 一种瑞司美替罗的合成方法
WO2024263714A1 (en) 2023-06-22 2024-12-26 Madrigal Pharmaceuticals, Inc. BIOMARKERS FOR TREATING LIVER DISORDERS WITH THR-β AGONISTS AND RELATED USES
CN119613386A (zh) * 2023-09-14 2025-03-14 杭州科巢生物科技有限公司 一种瑞司美替罗1,4-二氧六环溶剂化合物及其制备方法
CN117263870B (zh) * 2023-09-21 2026-02-06 江西同和药业股份有限公司 一种Resmetirom关键中间体III的制备方法
WO2025083699A2 (en) 2023-10-16 2025-04-24 Cipla Limited Resmetirom polymorphs and process thereof
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025164161A1 (ja) * 2024-01-29 2025-08-07 シオノギファーマ株式会社 カンナビジオールの溶媒和物及びカンナビジオールの精製方法
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
WO2025171032A1 (en) 2024-02-06 2025-08-14 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
WO2025191457A1 (en) * 2024-03-13 2025-09-18 Morepen Laboratories Limited Process for the preparation of pyridazinone derivative
CN119019375A (zh) * 2024-08-14 2024-11-26 奥锐特药业(天津)有限公司 一种瑞司美替罗新晶型及其制备方法
WO2026067708A1 (zh) * 2024-09-30 2026-04-02 齐鲁制药有限公司 瑞司美替罗晶型及其制备方法和用途
WO2026074443A1 (en) 2024-10-01 2026-04-09 Assia Chemical Industries Ltd. Solid state forms of resmetirom
CN119306670A (zh) * 2024-10-12 2025-01-14 北京海美桐医药科技有限公司 瑞司美替罗中间体、其合成方法和瑞司美替罗的合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5615272A (en) * 1979-07-17 1981-02-14 Ishihara Sangyo Kaisha Ltd N-benzoyl-n'-phenylurea compound, its preparation, and insecticide containing the same
GB0028429D0 (en) 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
ATE435870T1 (de) * 2003-01-28 2009-07-15 Academisch Ziekenhuis Leiden Aus ll-37 abgeleiteten peptidinhibitoren von toxinen
KR20050119652A (ko) 2003-03-24 2005-12-21 에프. 호프만-라 로슈 아게 역전사 효소 저해제로서의 벤질-피리다진온
ITRM20030363A1 (it) 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
US20060135455A1 (en) * 2004-06-01 2006-06-22 Reza Sheikhnejad Methods and compositions for the inhibition of gene expression
US7807647B2 (en) * 2004-06-01 2010-10-05 Pronai Therapeutics, Inc. Methods and compositions for cancer therapy
EP1812408B1 (en) 2004-11-02 2013-10-09 Northwestern University Pyridazine compounds, compositions and methods
HRP20100633T1 (hr) 2005-07-21 2011-01-31 F. Hoffmann - La Roche Ag Derivati piridazinona kao agonisti receptora tiroidnih hormona
ATE478053T1 (de) * 2007-06-06 2010-09-15 Torrent Pharmaceuticals Ltd Neuartige verbindungen
US8076334B2 (en) * 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
CA2884481C (en) 2012-09-17 2021-04-27 Madrigal Pharmaceuticals, Inc. Method of synthesizing thyroid hormone analogs and polymorphs thereof
US8858502B2 (en) 2012-10-10 2014-10-14 Alcon Research, Ltd. Systems and methods for external pressure sensing
JP6553067B2 (ja) 2014-02-14 2019-07-31 センプラ ファーマシューティカルズ，インコーポレイテッド 糖尿病および肝疾患を治療するための組成物および方法
CN110167557A (zh) 2016-10-18 2019-08-23 马德里加尔制药公司 用thr-beta兴奋剂治疗肝脏疾病或脂质疾病的方法
PT3807267T (pt) 2018-06-12 2025-05-22 Xizang Haisco Pharmaceutical Co Ltd Agonistas do recetor da hormona da tiroide e usos dos mesmos
AR115666A1 (es) 2018-07-02 2021-02-10 Madrigal Pharmaceuticals Inc Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo
CN119552152A (zh) 2018-10-12 2025-03-04 益方生物科技(上海)股份有限公司 甲状腺激素受体激动剂
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途

Also Published As

Publication number Publication date
BR122021024202B1 (pt) 2022-05-17
TW201906835A (zh) 2019-02-16
NO2026010I1 (no) 2026-03-03
RU2668960C2 (ru) 2018-10-05
US20240122936A1 (en) 2024-04-18
SG10201705984XA (en) 2017-08-30
US10894050B2 (en) 2021-01-19
RS67728B1 (sr) 2026-03-31
IL288133B1 (en) 2024-08-01
CA3111317A1 (en) 2014-03-20
CN108101851A (zh) 2018-06-01
IL275393B (en) 2022-01-01
EP3689853B1 (en) 2021-11-24
LT4406594T (lt) 2025-12-29
CN105008335A (zh) 2015-10-28
EP4406594A2 (en) 2024-07-31
LTPA2026507I1 (enExample) 2026-03-10
TWI681957B (zh) 2020-01-11
MY170520A (en) 2019-08-08
IN2015DN03133A (enExample) 2015-10-02
IL314360B2 (en) 2025-09-01
FR26C1009I1 (fr) 2026-04-17
DK3689853T3 (da) 2022-03-07
IL288133B2 (en) 2024-12-01
BR112015005891A2 (pt) 2017-08-08
KR101966490B1 (ko) 2019-08-14
ES3053122T3 (en) 2026-01-19
EP2895466A4 (en) 2016-08-10
IL288133A (en) 2022-01-01
PT4406594T (pt) 2025-11-28
US10376517B2 (en) 2019-08-13
KR20150056630A (ko) 2015-05-26
TWI652260B (zh) 2019-03-01
EP4023641A2 (en) 2022-07-06
PL4406594T3 (pl) 2026-03-30
IL314360A (en) 2024-09-01
AR092872A1 (es) 2015-05-06
DK2895466T3 (da) 2020-06-08
RU2015114327A (ru) 2016-11-10
JP6532931B2 (ja) 2019-06-19
KR102363776B1 (ko) 2022-02-15
MX2015003418A (es) 2016-04-04
AU2013315017C1 (en) 2017-11-23
WO2014043706A8 (en) 2017-10-19
EP4023641A3 (en) 2022-09-14
ES2907926T3 (es) 2022-04-27
IL259610B (en) 2020-06-30
JP2022078218A (ja) 2022-05-24
JP2019048856A (ja) 2019-03-28
KR20180131647A (ko) 2018-12-10
CA2884481C (en) 2021-04-27
DK4406594T3 (da) 2025-11-03
HK1212682A1 (en) 2016-06-17
CA3111317C (en) 2023-08-29
SG10202006058QA (en) 2020-08-28
AU2013315017B2 (en) 2017-07-27
ZA201501795B (en) 2021-10-27
RU2018128393A3 (enExample) 2019-04-16
TWI755628B (zh) 2022-02-21
SMT202500439T1 (it) 2026-05-12
KR20210083381A (ko) 2021-07-06
CA2884481A1 (en) 2014-03-20
TW202134217A (zh) 2021-09-16
TWI804870B (zh) 2023-06-11
EP4406594B1 (en) 2025-09-10
SG11201501907YA (en) 2015-04-29
IL265030B (en) 2020-07-30
CN105008335B (zh) 2018-12-21
EP4023641B1 (en) 2024-05-01
CA3090070A1 (en) 2014-03-20
JP6899413B2 (ja) 2021-07-07
EP2895466B1 (en) 2020-03-25
JP2020109090A (ja) 2020-07-16
US20230210856A1 (en) 2023-07-06
IL259610A (en) 2018-07-31
EP2895466A1 (en) 2015-07-22
EP4691557A3 (en) 2026-03-18
WO2014043706A1 (en) 2014-03-20
US9266861B2 (en) 2016-02-23
FIC20265007I1 (fi) 2026-03-03
RU2018128393A (ru) 2019-03-14
NL301369I2 (nl) 2026-03-30
EP4691557A2 (en) 2026-02-11
US11564926B2 (en) 2023-01-31
JP7436542B2 (ja) 2024-02-21
JP2024056793A (ja) 2024-04-23
NZ705827A (en) 2018-07-27
US11986481B2 (en) 2024-05-21
JP2015535817A (ja) 2015-12-17
KR20200023528A (ko) 2020-03-04
US20180228807A1 (en) 2018-08-16
JP7038745B2 (ja) 2022-03-18
ES2795450T3 (es) 2020-11-23
JP6765408B2 (ja) 2020-10-07
JP2018080188A (ja) 2018-05-24
JP6616688B2 (ja) 2019-12-04
IL275393A (en) 2020-07-30
US20210161904A1 (en) 2021-06-03
IL237628B (en) 2019-07-31
US9968612B2 (en) 2018-05-15
US20240148742A1 (en) 2024-05-09
SI4406594T1 (sl) 2026-03-31
US20150203473A1 (en) 2015-07-23
TW201425300A (zh) 2014-07-01
AU2013315017A1 (en) 2015-04-02
US20160243126A1 (en) 2016-08-25
EP3689853A1 (en) 2020-08-05
IL237628A0 (en) 2015-04-30
HRP20251398T1 (hr) 2026-03-13
EP4406594A3 (en) 2024-11-06
JP2025179154A (ja) 2025-12-09
JP2020015739A (ja) 2020-01-30
US20190381053A1 (en) 2019-12-19
IL320269A (en) 2025-06-01
CA3090070C (en) 2023-01-24
FI4406594T3 (fi) 2025-11-26
MX364661B (es) 2019-05-03
KR102138750B1 (ko) 2020-07-29
MX395148B (es) 2025-03-24
MX2018014924A (es) 2020-09-02
IL314360B1 (en) 2025-05-01
TW201946917A (zh) 2019-12-16

Similar Documents

Publication Publication Date Title
MY170520A (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
IN2014CN00989A (enExample)
PH12013501727A1 (en) Heteroaryl derivatives as alpha7 nachr modulators
AR084824A1 (es) Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
NZ742200A (en) Treatment of osteoarthritis
NI201100211A (es) Método mejorado para sintetizar pirfenidona
WO2011123668A3 (en) Stereoselective synthesis of phosphorus containing actives
UA97478C2 (ru) Кристаллическая форма vi агомелатина, способ ее приготовления (варианты) и фармацевтическая композиция, которая ее содержит
MY159252A (en) Process for the preparation of dopo-derived compounds and compositions thereof
MX2014001481A (es) Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio.
PH12013501859A1 (en) Indolecarboxamides and benzimidazolecarboxamides as insecticides and acaricides
MX364833B (es) Sintesis de compuestos polihidroxi cromenona y sus efectos anti-tumor.
DK2190426T3 (da) Griseofulvin-analoger til behandling af cancer ved hæmning af centrosomal clusterdannelse
MX2010009860A (es) Sintesis total de salinosporamida a y sus analogos.
MX337721B (es) Compuestos de heteroarilo como ligandos del receptor 5-ht4.
MX339858B (es) Compuestos novedosos como ligandos del receptor h3 de la histamina.
NZ628796A (en) Pure erlotinib
MX2011012068A (es) Nucleosidos 2'-fluoro arabino y su utilizaicon.
WO2012159027A3 (en) Osw-1 analogs and conjugates, and uses thereof
TN2012000619A1 (fr) Forme cristalline delta du sel d'arginine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
WO2014199244A3 (en) Crystalline imatinib mesylate process
GB201103578D0 (en) Dipyridinium derivatives
NZ746298A (en) Hydrates of a phenoxypyridazinone compound and its use in the manufacture of a medicament for treating a disease characterized by resistance to thyroid hormone
MX2015007885A (es) Compuestos farmaceuticos.
AR083828A1 (es) Formas cristalinas de un acido alcoxiimidazol-1-ilmetilfenil carboxilico

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2021 BY COMPUTER PACKAGES INC

Effective date: 20200901

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2022 BY COMPUTER PACKAGES INC

Effective date: 20210830

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2023 BY COMPUTER PACKAGES INC

Effective date: 20220830

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2024 BY COMPUTER PACKAGES INC

Effective date: 20230830

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2025 BY COMPUTER PACKAGES INC

Effective date: 20240830

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2026 BY COMPUTER PACKAGES INC

Effective date: 20250830